3-[3-(4-Methoxyphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-2(1H)-quinolinone manufacturers
- Ceranib-2
-
- $47.00
-
2026-05-11
- CAS:1402830-75-4
- Purity: 98.49%
- Supply Ability: 10g
- Ceranib-2
-
- $47.00
-
2026-05-11
- CAS:1402830-75-4
- Purity: 98.49%
- Supply Ability: 10g
|
| | 3-[3-(4-Methoxyphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-2(1H)-quinolinone Basic information |
| Product Name: | 3-[3-(4-Methoxyphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-2(1H)-quinolinone | | Synonyms: | 3-[3-(4-Methoxyphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-2(1H)-quinolinone;3-[3-(4-Methoxyphenyl)-1-oxo-2-propenyl]-4-phenyl-2(1H)-quinolinone;2(1H)-Quinolinone, 3-[3-(4-methoxyphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-;Ceranib-2 >=98% (HPLC);Ceranib-2, 10 mM in DMSO;3-[(2E)-3-(4-Methoxyphenyl)prop-2-enoyl]-4-phenyl-1,2-dihydroquinolin-2-one | | CAS: | 1402830-75-4 | | MF: | C25H19NO3 | | MW: | 381.42326 | | EINECS: | 802-692-7 | | Product Categories: | | | Mol File: | 1402830-75-4.mol | ![3-[3-(4-Methoxyphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-2(1H)-quinolinone Structure](CAS/20150408/GIF/1402830-75-4.gif) |
| | 3-[3-(4-Methoxyphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-2(1H)-quinolinone Chemical Properties |
| storage temp. | -20°C | | solubility | DMSO: soluble20mg/mL, clear | | form | powder | | color | white to beige |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | 3-[3-(4-Methoxyphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-2(1H)-quinolinone Usage And Synthesis |
| Description | Ceranib-2 is a ceramidase inhibitor that inhibits ceramidase activity (IC50 = 28 μM in SKOV3 cells). It also increases intracellular accumulation of various ceramides, including C14 ceramide , C24 ceramide , C26 ceramide, and C26:1 ceramide, and total ceramide levels and decreases levels of dihydrosphingosine, sphingosine, and sphingosine-1-phosphate in SKOV3 cells. In vivo, ceranib-2 (20 and 50 mg/kg, i.p.) reduces tumor volume in a JC mammary adenocarcinoma mouse syngeneic tumor model. | | Uses | Ceranib-2 is a potent and nonlipid ceramidase inhibitor that inhibits cellular ceramidase activity with an IC50 of 28 μM in SKOV3 cells. Ceranib-2 induces the accumulation of multiple ceramide species, decreases levels of sphingosine and sphingosine-1-phosphate (S1P), and induces cell apoptosis. Anticancer activity[1][2]. | | in vivo | Ceranib-2 (20-50 mg/kg; intraperitoneal injection; daily for 5 days per week; for 3 weeks; female Balb/c mice) treatment delays tumor growth in a syngeneic tumor model without hematologic suppression or overt signs of toxicity[1].
Intraperitoneal administration of 50 mg/kg Ceranib-2 results in progressive increases in its circulating levels, reaching a peak plasma concentration of approximately 40 μM at the 2 hr time point. Ceranib-2 appears to be cleared with a half-life of less than 2 hr[1]. | Animal Model: | Female Balb/c mice injected with JC murine mammary adenocarcinoma cells[1] | | Dosage: | 20 mg/kg or 50 mg/kg | | Administration: | Intraperitoneal injection; daily for 5 days per week; for 3 weeks | | Result: | Delayed tumor growth in a syngeneic tumor model.
|
| | References | [1] Draper JM, et al. Discovery and evaluation of inhibitors of human ceramidase. Mol Cancer Ther. 2011 Nov;10(11):2052-61. DOI:10.1158/1535-7163.MCT-11-0365
[2] Kus G, et al. Induction of apoptosis in prostate cancer cells by the novel ceramidase inhibitor ceranib-2. In Vitro Cell Dev Biol Anim. 2015 Nov;51(10):1056-63. DOI:10.1007/s11626-015-9932-9 |
| | 3-[3-(4-Methoxyphenyl)-1-oxo-2-propen-1-yl]-4-phenyl-2(1H)-quinolinone Preparation Products And Raw materials |
|